特一药业集团股份有限公司

Core Points - The company guarantees the authenticity, accuracy, and completeness of the quarterly report, with all board members assuming legal responsibility for any misstatements or omissions [2][3] - The first quarter report has not been audited, and the company has made retrospective adjustments to previous accounting data [3][4] Financial Data - The core product, cough relief tablets, achieved sales of 217 million pieces, with brand building investments reaching 106 million yuan [4] - The company is undergoing marketing organizational changes and brand marketing construction, which have shown initial results but may pose risks to short-term operating performance [4][5] Shareholder Information - The report includes details on the total number of common stock shareholders and the top ten shareholders, although there are no changes in the lending of shares for the top shareholders [4]